FDA Clears Phase 2a Trial of Dual-Target Antibody NAV-240 for HS

Navigator Medicines has begun dosing patients in an FDA-cleared phase 2a trial of NAV-240, a dual-target antibody blocking TNF and O40L in moderate to severe HS.